Close Icon

Safety and Combination Products

When Drugs and Devices Come Together, Safety Considerations Get More Complex. Dr. Khaudeja Bano, Vice President Combination Product Quality at Amgen, joined the Safety Signals Podcast to discuss the unique safety challenges posed by products that include both drugs and devices. In this episode of Safety Signals, Dr. Bano talks about:
  1. The different safety approaches in the drug and device worlds
  2. Supporting women in clinical research
  3. Why safety and quality organizations need to speak the same language
“The word ‘signal’ means nothing to my quality peers and the word ‘trend’ means nothing to my safety peers,” Dr. Bano says. “So some of our growing pains are around truly bringing the cross-functional team together to start speaking the same language.” Listening on a desktop and can’t see the links? Just search for Safety Signals on your favorite podcast player. The views of the hosts and guests featured on Safety Signals are their own and do not necessarily reflect the views of Saama or the individual companies for which the guests may work.
About Saama Safety Signals

Introducing Safety Signals, the show for pharmacovigilance professionals, benefit risk managers, epidemiologists, and other patient safety stakeholders. From pharma leaders to academics and scientists, we provide expert perspectives on the challenges, opportunities, and technologies that are shaping the future of the safety sciences. Get ready to be inspired and energized as you work to reduce the risk of life-changing–and life SAVING–medical treatments.

Listen & Subscribe
Solutions

Active Safety Analytics for Pharma (ASAP)

Operations Insights

Meet Your Hosts & Guests

Benzi Mathew

Benzi
Mathew

Vice President & Partner
Saama Technologies

Linkedin-in Twitter Envelope
Ramprasad Keshavamurthy

Ramprasad
Keshavamurthy

Senior Director
Saama Technologies

Linkedin-in Envelope
khaudeja bano

Dr. Khaudeja
Bano

Vice President Combination Product Quality at Amgen

Linkedin-in

Terms & Conditions

By inquiring about Saama’s Database Lock in a Day, you agree to be contacted by Saama and to allow Saama to use, maintain, store, and protect your personal data in accordance with our Privacy Policy.

Eligibility details are for informational purposes only. Saama, in its sole discretion, will determine your eligibility based on the information you disclose as part of the intake process. If Saama determines that you are eligible to participate, you will be notified by separate email. Eligibility depends on certain criteria, such as the size of your company, the types of clinical trials you sponsor, and the number of patients in–and stages of–your current clinical trials.

By completing the request form, you represent that you have authority to proceed on behalf of your company. Should you agree to participate, you agree to reasonably cooperate with Saama in following the guidelines and procedures required for integrating, standardizing, and analyzing your data. Participation requires the use of our Smart Data Quality application, a technology-agnostic AI engine that sits on top of your current infrastructure. The application can be used immediately, and you’re only charged for the services you use based on a predetermined estimate.

Information you share with Saama during your participation may be anonymized and/or aggregated, and made available publicly in Saama marketing materials. This information may include: types of systems and processes involved, types of departments involved, and size and regional location of your company. Such information will never be directly associated with you, nor will you or your company be identifiable without express written permission.